$20m-$39.9m

UCSD-founded Shape Therapeutics has collected series A cash from NEA and CureDuchenne Ventures to progress its RNA gene editing technology.

Genomics bioinformatics platform developer PierianDx, a Washington University in St Louis spinout, has raised fresh capital to advance its business strategy.

Dai-ichi Life has led the final close for the Japan-based financial technology developer’s $38.8m series C round, which was already backed by Tokyo University of Science Investment Management Company.

University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from OSI and GlaxoSmithKline’s SR One.

Livzon Pharmaceutical Group has been identified as an investor by MIT spinout Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.

Partners HealthCare has co-led a series A round for ZielBio to drive forward the development of a cancer treatment based on research at University of Virginia.

Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.